Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Revenue of Nkarta, Inc. (NKTX)
Revenue in 2023 (TTM): $
According to Nkarta, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Nkarta, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-5,869,000 | $-120,481,000 | $-117,501,000 | $-117,501,000 |
| 2022 | $ | $-6,572,000 | $-107,265,000 | $-113,837,000 | $-119,425,000 |
| 2021 | $ | $-2,123,000 | $-83,952,000 | $-86,075,000 | $-83,949,000 |
| 2020 | $ | $-1,048,000 | $-90,313,000 | $-91,361,000 | $-50,409,000 |
| 2019 | $115.39 K | $98.17 K | $-20,049,739 | $-21,075,835 | $-22,883,898 |
| 2018 | $6.55 M | $2.3 M | $-91,289 | $-274,503 | $-274,503 |